Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Sell
17
TRAW Quote, Financials, Valuation and Earnings
Last price:
$1.44
Seasonality move
:
9.1%
Day range:
$1.49 - $1.55
52-week range:
$1.36 - $19.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
10.87x
P/B ratio:
2.78x
Volume:
56.7K
Avg. volume:
56.8K
1-year change:
-90.2%
Market cap:
$7.7M
Revenue:
$226K
EPS (TTM):
-$141.47
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Traws Pharma has 294.74% upside to fair value with a price target of -- per share.
TRAW vs. S&P 500
-
Over the past 5 trading days, Traws Pharma has underperformed the S&P 500 by -16.03% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Traws Pharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Traws Pharma has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Traws Pharma reported revenues of $57K.
Earnings Growth
-
Traws Pharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Traws Pharma reported earnings per share of -$8.81.
Enterprise value:
-13.6M
EV / Invested capital:
--
Price / LTM sales:
10.87x
EV / EBIT:
--
EV / Revenue:
-60.29x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
0.46x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-736.98%
Net Income Margin (TTM):
-62294.25%
Return On Equity:
-124.39%
Return On Invested Capital:
-124.39%
Operating Margin:
-14975.44%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $226K | $226K | $226K | $56K | $56K | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$19.6M | -$20.3M | -$24.9M | -$4.5M | -$5.3M | |
| EBITDA | -$19.6M | -$20.3M | -$24.9M | -$4.5M | -$5.3M | |
| Diluted EPS | -$22.75 | -$22.62 | -$114.12 | -$4.98 | $22.44 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $19.8M | $55.4M | $39.3M | $22.7M | $25M | |
| Total Assets | $20M | $55.5M | $39.4M | $22.7M | $25M | |
| Current Liabilities | $10M | $6.1M | $8M | $9.2M | $11.5M | |
| Total Liabilities | $13.8M | $9.4M | $11.1M | $12M | $56.6M | |
| Total Equity | $6.2M | $46.1M | $28.3M | $10.7M | -$31.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$16.3M | -$17.9M | -$29.8M | -$4.4M | -$4M | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | $20M | |
| Free Cash Flow | -$16.3M | -$17.9M | -$29.8M | -$4.4M | -$4M | |
TRAW
Sector
Market Cap
$7.7M
$34.4M
Price % of 52-Week High
7.82%
44.25%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-90.21%
-39.44%
Beta (5-Year)
1.431
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.68
200-day SMA
Sell
Level
$6.10
Bollinger Bands (100)
Sell
Level
2.17 - 7.61
Chaikin Money Flow
Sell
Level
-21.6M
20-day SMA
Sell
Level
$1.89
Relative Strength Index (RSI14)
Sell
Level
29.77
ADX Line
Sell
Level
24.22
Williams %R
Buy
Level
-87.4016
50-day SMA
Sell
Level
$2.69
MACD (12, 26)
Sell
Level
-0.38
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
31.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-38.7033)
Sell
CA Score
(Annual)
Level (-9.4913)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (33.5767)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
Stock Forecast FAQ
In the current month, TRAW has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The TRAW average analyst price target in the past 3 months is --.
-
Where Will Traws Pharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that Traws Pharma share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Traws Pharma?
Analysts are divided on their view about Traws Pharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Traws Pharma is a Sell and believe this share price will drop from its current level to --.
-
What Is Traws Pharma's Price Target?
The price target for Traws Pharma over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is TRAW A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Traws Pharma is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of TRAW?
You can purchase shares of Traws Pharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Traws Pharma shares.
-
What Is The Traws Pharma Share Price Today?
Traws Pharma was last trading at $1.44 per share. This represents the most recent stock quote for Traws Pharma. Yesterday, Traws Pharma closed at $1.52 per share.
-
How To Buy Traws Pharma Stock Online?
In order to purchase Traws Pharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Is NextEra Energy a Stock to Hold Forever?
NextEra Energy (NYSE:NEE) share price sold off hard in recent…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
39
RGC alert for Apr 29
Regencell Bioscience Holdings [RGC] is down 11.18% over the past day.
Buy
76
EXOD alert for Apr 29
Exodus Movement [EXOD] is down 3.2% over the past day.
Sell
48
SBGSY alert for Apr 29
Schneider Electric SE [SBGSY] is down 0.17% over the past day.
